Nykredit A/S’s Cytokinetics CYTK Stock Holding History

Nykredit A/S’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$444K	Buy	+5,213	New	+$374K	﹤0.01%	725

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nykredit A/S's CYTK Position: Q2 2026 in Review

Nykredit A/S opened a new position in Cytokinetics (CYTK) in Q2 2026: 5,213 shares worth $444K. The stake represents ﹤0.01% of the portfolio and ranks #725 among its holdings.

329 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Nykredit A/S held 5,213 shares of Cytokinetics worth $444K as of Q2 2026.
Cytokinetics was a new Nykredit A/S position in Q2 2026.
Cytokinetics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #725 holding.
329 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.